The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Alnylam Pharmaceuticals 9-Day RSI Related Terms
XTER:DUL vs RVMD, ONC, MRNA: 9-Day RSI Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (XTER:DUL) has a 9-Day RSI of 58.43 as of Jul. 13, 2026. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #531 out of 1422 companies in the Biotechnology industry, placing it in the top 37.3%.
Is Alnylam Pharmaceuticals' 9-Day RSI too high?
Alnylam Pharmaceuticals' current 9-Day RSI is 58.43. The Biotechnology industry median 9-Day RSI is 50.12. Alnylam Pharmaceuticals' value of 58.43 is 16.6% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #531 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' 9-Day RSI compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #531 out of 1422 companies for 9-Day RSI. This puts Alnylam Pharmaceuticals in the upper half of its industry. The industry median 9-Day RSI is 50.12. Alnylam Pharmaceuticals' value of 58.43 is 16.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.12, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current 9-Day RSI of 58.43 is 16.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current 9-Day RSI is 58.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (XTER:DUL) is currently considered Significantly Undervalued. The stock's GF Value™ is €485.21, compared to a current price of €278.00 — trading 42.7% below its estimated fair value. The current 9-Day RSI is 58.43 and 16.6% above the Biotechnology industry median of 50.12. Alnylam Pharmaceuticals' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Alnylam Pharmaceuticals (XTER:DUL), the current 9-Day RSI is 58.43 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (XTER:DUL) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of €278.00 is trading 42.7% below its estimated GF Value™ of €485.21.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for XTER:DUL:
9-Day RSI: 58.43
GF Value™: €485.21 vs. price of €278.00 (42.7% below fair value)
Industry Position: 16.6% above the Biotechnology median (#531 of 1422)
No single metric tells the full story. See the XTER:DUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
74GF Score
Get the complete analysis for XTER:DUL
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:DUL has been successfully added to your 